A report signified the implications of acetylcholinesterase inhibitors (AChEIs), rivastigmine tartrate, and donepezil in AD therapeutics targeting MARK4 (Shamsi et al., 2020a). This evidence concerns the gene MARK4 and Alzheimer disease.